Literature DB >> 20222793

Clinical application of breast cancer risk assessment models.

Kaylene Ready1, Jennifer K Litton, Banu K Arun.   

Abstract

With the evolving availability of testing for genetic cancer syndromes, oncologists now are increasingly expected to review family histories and to give a genetic risk assessment as part of their care for breast cancer. The most important of these breast cancer genetic syndromes identified to date have been those associated with the BRCA1 and BRCA2 genes. Therefore, the proper identification of potentially affected families and providing risk assessment estimates will be ever more essential. This review outlines several different available breast cancer risk assessment models. Risk models for the development of breast cancer as well as risk models that estimate the chance of having a genetic cancer syndrome are discussed. Their clinical applications are also outlined and clinical situations appropriate for each model are reviewed.

Entities:  

Mesh:

Year:  2010        PMID: 20222793     DOI: 10.2217/fon.10.5

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  4 in total

1.  Implications of single nucleotide polymorphisms in CD44 exon 2 for risk of breast cancer.

Authors:  Juhua Zhou; Prakash S Nagarkatti; Yin Zhong; Jiajia Zhang; Mitzi Nagarkatti
Journal:  Eur J Cancer Prev       Date:  2011-09       Impact factor: 2.497

2.  Breast cancer in the young: role of the geneticist.

Authors:  Ashley H Woodson; Jessica L Profato; Kimberly I Muse; Jennifer K Litton
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

Review 3.  Assessing Risk of Breast Cancer: A Review of Risk Prediction Models.

Authors:  Geunwon Kim; Manisha Bahl
Journal:  J Breast Imaging       Date:  2021-02-19

4.  Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women.

Authors:  Juncheng Dai; Zhibin Hu; Yue Jiang; Hao Shen; Jing Dong; Hongxia Ma; Hongbing Shen
Journal:  Breast Cancer Res       Date:  2012-01-23       Impact factor: 6.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.